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IntroductIon
The inflammatory condition associated with obesity is consid-
ered to play a major role in the pathogenesis of obesity-related 
morbidities like cardiovascular disease and type 2 diabetes 
mellitus (1). Several inflammatory molecules have been shown 
to be involved. For instance, tumor necrosis factor-α plasma 
levels are increased in severely obese patients (2,3) and tumor 
necrosis factor-α knockout mice do not develop insulin resist-
ance after diet-induced obesity (4). Moreover, selective upreg-
ulation of IκB kinase-β, an inducer of nuclear factor-κB in liver 
results in decreased insulin sensitivity (5).
So far, most studies have focused on the role of macrophage 
activation and accumulation in adipose tissue, which has been 
shown to contribute significantly to insulin resistance (6). 
However, it appears that there is a more general activation of 
the immune system. For instance, levels of acute-phase proteins 
(C-reactive protein and α1-acid glycoprotein) are increased in 
morbid obesity and decreased after surgery-induced weight 
loss (3). Moreover, circulating levels of endothelial activation 
markers are increased in obesity, indicating an activation of 
endothelial cells (7). Furthermore, the complement system is 
activated in morbid obesity which decreases after weight loss 
(8). Collectively, these findings indicate that the immune sys-
tem is activated in obesity.
Neutrophils represent one of the most prominent 
 components of the innate immune system, displaying strong 
phagocytic and antimicrobial activity. Their antimicrobial 
activity is mainly based on specific proteins stored in gran-
ules or in the cytoplasm, such as myeloperoxidase (MPO) 
and calprotectin. MPO is a potent enzyme stored in the 
azurophilic granules of neutrophils, which is secreted upon 
neutrophil activation. MPO generates numerous reactive 
oxidants and radicals, which cause oxidative damage to pro-
teins, lipoproteins,  lipids, and DNA of target cells (9). These 
characteristics of MPO are also important in the relation of 
MPO with cardiovascular  disease. Zheng et al. showed that 
Apolipoprotein-A1, the major lipoprotein of high-density 
lipoprotein, is a specific target for MPO in atheroma, which 
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could lead to plaque instability (10). Moreover, the product of 
MPO-controlled catalysis of hydrogen peroxide, hypochlo-
rous acid, is thought to play a central role in the etiology 
of atherosclerosis (11). Calprotectin is a cytoplasmic bac-
teriostatic protein, which is released upon activation (12). 
Neutrophil activation is also accompanied by translocation 
of the glycoprotein CD66b from the secondary granules to 
the outer cell membrane (13).
Earlier studies have shown that whereas the number of 
neutrophils remains unchanged in severely obese patients, 
expression of CD62L, an adhesion molecule on the neu-
trophil surface, was depressed (14). Expression of other 
activation markers by neutrophils, such as the Fc receptor 
CD16 and the adhesion molecule CD11b as well as plasma 
levels of the activation marker elastase were similar between 
obese patients and normal weight controls (14,15). Therefore, 
the current view is that neutrophils are not activated in the 
severely obese individual. However, it was reported that the 
total number of circulating neutrophils was increased in obese 
individuals (16,17). In addition, evidence for a role of MPO 
in the development of obesity in mice was recently reported. 
Overexpression of MPO in transgenic mice led to enhanced 
weight gain on a high fat diet (18). Given these results and 
the notion that other components of the innate immune sys-
tem are activated in severely obese subjects, we set out to 
evaluate the activation state of neutrophils in severely obese 
subjects. Here, it is reported that, in line with the activation 
of the innate immune response in morbid obesity, increased 




All participants gave written informed consent. The study was 
approved by the local ethical committee of the Academic Hospital 
Maastricht.
Plasma levels of the neutrophil activation markers MPO and calpro-
tectin were compared between 37 severely obese individuals and 9 nor-
mal weight control subjects (study 1A). Membrane CD66b expression 
on neutrophils was studied in seven severely obese subjects and com-
pared to CD66b expression on neutrophils of six normal weight con-
trols (study 1B). The effect of bariatric surgery on neutrophil activation 
was studied in 15 consecutive subjects, admitted to the Department of 
Surgery of the University Hospital Maastricht (study 2). Characteristics 
of the different study groups are depicted in Table 1. All subjects were 
selected to be otherwise healthy according to history, clinical examina-
tion, and whenever possible laboratory findings, which means that no 
overt signs of type 2 diabetes mellitus, hypertension, nonalcoholic fatty 
liver disease, and other cardiovascular diseases were present. Moreover, 
patients using anti-inflammatory medication like aspirin, statins, and 
fibrates were excluded.
For studies 1A and 2, blood samples were collected after at least 8-h 
fasting using evacuated blood collection tubes containing EDTA and 
processed as previously described (3). In study 1B, whole blood samples 
were used. All samples were processed immediately for fluorescence 
activated cell sorting.
Immunoassays
Plasma concentrations of MPO and calprotectin were determined 
using sandwich enzyme-linked immunosorbent assays (HyCult bio-
technology, Uden, the Netherlands). All plasma samples were analyzed 
in the same run. The intra- and interassay coefficients of variance of the 
various assays were <10%.
Fluorescence activated cell sorting analysis
Fluorescence activated cell sorting analysis to detect membrane 
CD66b expression on neutrophils was performed using the following 
protocol. Whole blood (100 μl) (EDTA) was incubated with a fluo-
rescein isothiocyanate–labeled antibody against CD66b. Phosphate 
buffered saline and a fluorescein isothiocyanate–labeled isotype 
antibody were used as negative control. After 30 min of incubation 
in the dark, erythrocytes were lysed and the vials were centrifuged 
at 400 g. The supernatant was discarded and the cells were washed 
twice with phosphate buffered saline–0.1% bovine serum albumin. 
Finally, cells were resuspended in 1% paraformaldehyde solution 
and fluorescence activated cell sorting analysis was performed the 
same day on the FACSCalibur using Cellquest software (Becton 
Dickinson, Franklin lakes, NJ). Data are expressed as mean fluores-
cence intensity.
Immunohistochemistry
Four-micrometer slices of formalin fixed, paraffin embedded visceral 
adipose (omentum) and muscle (rectus abdominus) tissue were stained 
for neutrophil infiltration using an antibody directed against MPO. In 
short, slides were deparaffinized, rehydrated, and incubated for 15 min 
in methanol–0.6% H2O2 to block endogenous peroxidases. Thereafter, 
slides were incubated with 10% goat serum in Tris buffered saline–0.1% 
bovine serum albumin to prevent nonspecific binding of the secondary 
antibody. After washing with Tris buffered saline, slides were incubated 
with rabbit anti human MPO (1:1,000). Goat anti rabbit IgG antibody 
labeled with HRP was used as a secondary antibody. 3-Amino-9-
 ethylcarbazole was used as substrate for peroxidase. Hematoxylin was 
used as a counterstaining.
reagents and materials
Bovine serum albumin was purchased from Sigma (St Louis, MO). 
Fluorescein isothiocyanate–labeled antibodies against CD66b (clone 
80H3) and the isotype control were purchased from Serotec (Kidlington, 
England). Polyclonal rabbit anti human MPO was purchased from 
Dako (Glostrup, Denmark).
statistical analysis
All data are expressed as mean ± s.d. In studies 1A and 1B, due 
to unpaired and nonparametrically distributed data, results were 
compared using the Mann–Whitney test. In study 2, due to paired 
and nonparametrically distributed data, results were compared 
using the Wilcoxon sign rank test. A P value <0.05 was considered 
statistically significant.
results
Plasma markers of neutrophil activation are increased in 
morbid obesity
Table 1 summarizes the patient characteristics of the severely 
obese and normal weight controls studied.
The plasma levels of the neutrophil activation markers 
MPO and calprotectin were measured in severely obese and 
normal weight controls (study group 1A). Both circulating 
MPO and calprotectin levels were significantly increased in 
severely obese subjects as compared to healthy controls. The 
levels of MPO were 27.1 ± 10.8 ng/ml in the severely obese 
group whereas normal weight controls showed plasma levels 
of 17.3 ± 5.5 ng/ml (P < 0.001). For calprotectin, plasma levels 
were 115.5 ± 43.5 ng/ml in the severely obese group, whereas 
plasma levels of normal weight controls were 65.1 ± 23.1 ng/ ml 
(P < 0.001) (Figure 1).
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It has been shown that immune activation diminishes 
 during ageing (19). Also immune activation is thought to be 
more vigorous in women (20). However, no correlation was 
found between plasma MPO and calprotectin levels and age or 
sex. Also BMI was not correlated with MPO or calprotectin. In 
contrast, plasma MPO and plasma calprotectin levels showed 
a significant correlation (R2 = 0.28, P < 0.001), indicating that 
they represent neutrophil activation (Figure 2).
cd66b expression on neutrophils is increased in severely 
obese individuals
To further explore the hypothesis that neutrophils are acti-
vated in morbid obesity, we assessed the activation marker of 
circulating neutrophils, CD66b, using flow cytometry. Surface 
CD66b expression was measured in a smaller group of seven 
severely obese and six normal weight healthy controls (see 
for characteristics Table 1, study group 1B). Like MPO and 
calprotectin plasma levels, CD66b membrane expression was 
significantly increased in severely obese individuals, 177.3 ± 
43.7 vs. 129.7 ± 9.2 (P < 0.01) (Figure 3).
the effect of bariatric surgery on plasma markers of 
neutrophil activation (study group 2)
Weight loss after bariatric surgery is associated with decreased 
plasma levels of inflammatory mediators. Interestingly, 
MPO levels remained unchanged after bariatric surgery 
(19.7 ± 4.1 ng/ ml preoperative and 21.5 ± 6.8 ng/ml 2 years 
 postoperative). On the other hand, 2 years after bariatric 
surgery,  calprotectin levels decreased (11 out of 15 patients) 
 significantly from a mean of 119.6 ± 31.5 to a mean of 93.9 ± 
42.7 ng/ml (P < 0.001). (Figure 4). The outliers of the calpro-
tectin group were not identical with the outliers in the MPO 
group. Correlation analyses of the change in BMI and ΔMPO 
or calprotectin showed no significant correlation.
table 1 characteristics of the study populations
Study group 1A Study group 1B Study group 2









(n = 15) Postoperative
BMI (kg/m2) 46.0 ± 6.0 22.8 ± 3.0 43.8 ± 6.7 22.8 ± 2.6 46.0 ± 4.9 36.2 ± 7.4
Age (year) 37 ± 10 31 ± 11 47 ± 7 44 ± 12 36 ± 10
Sex (male/female) 5/32 2/7 3/4 3/3 1/14
Plasma MPO and calprotectin levels were compared between severely obese subjects and normal weight controls in study 1A. In study 1B, CD66b expression was 


































Figure 1 Circulating MPO and calprotectin levels in severely obese and 
normal weight subjects (study group 1A). The levels of MPO were 27.1 ± 
10.8 ng/ml in the severely obese group whereas normal weight controls 
showed plasma levels of 17.3 ± 5.5 ng/ml (P < 0.001). For calprotectin, 
plasma levels were 115.5 ± 43.5 ng/ml in the severely obese group, 
whereas plasma levels of normal weight controls were 65.1 ± 23.1 ng/ml 
(P < 0.001). MPO, myeloperoxidase.















Figure 2 Plasma MPO and calprotectin levels show a significant 





























Figure 3 CD66b expression on the neutrophil cell membrane quantified 
by mean fluorescence intensity in severely obese and normal weight 
subjects (study group 1B). CD66b expression was significantly increased 
in severely obese individuals, 177.3 ± 43.7 vs. 129.7 ± 9.2 (P < 0.01).
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Absence of neutrophils in adipose and muscle tissue
To determine whether the increased neutrophil activation is 
accompanied by enhanced neutrophil infiltration of adipose 
or muscle tissue, immunohistochemical staining of MPO was 
performed. From 17 severely obese subjects, subcutaneous and 
visceral adipose tissue as well as skeletal muscle was stained 
for MPO. No MPO positive cells were located outside the vas-
culature of these tissues (Figure 5). In seven of these patients, 
plasma levels of calprotectin and MPO were measured as part 
of study 1A and shown to be increased compared with normal 
weight controls.
dIscussIon
The inflammatory condition in severely obese subjects is char-
acterized by activation of several components of the innate 
immune response. This is illustrated by increased plasma lev-
els of acute-phase proteins, endothelial cell activation mark-
ers, complement factors, and cytokines derived from activated 
macrophages. Remarkably little is known about the activation 
of neutrophils, a central component in innate immunity, in 
obesity. Thus far, available data suggest that neutrophils are less 
activated in morbid obesity (14,15). This is in contrast to the 
overt evidence that the innate immune system is activated in 
morbid obesity. Therefore, we set out to determine the degree 
of neutrophil activation using plasma levels of calprotectin and 
MPO and neutrophil membrane expression of CD66b. MPO 
and calprotectin are primarily secreted by neutrophils although 
a minor secretion by activated monocytes cannot be excluded 
(9,12,21) CD66b on the other hand is specifically expressed on 
the outer cell membrane of granulocytes and its expression is 
enhanced upon activation of the cells (22,13) making CD66b a 
suitable marker for neutrophil activation.
We show increased plasma levels of MPO and calprotec-
tin in severely obese patients, strongly indicating neutrophil 
activation. The observed increased neutrophil-specific CD66b 
expression also strongly supports neutrophil activation in 
morbid obesity. A possible mechanism for the activation of 
neutrophils could be the increased plasma levels of leptin and 
tumor necrosis factor-α observed in morbid obesity. Leptin has 
been reported to activate neutrophils via indirect induction of 
tumor necrosis factor-α secretion by monocytes (23).
Our findings contrast with the study of Cottam et al., who 
reported a lower CD62L expression on neutrophils of severely 
obese individuals as compared to neutrophils of normal weight 
controls (14). They concluded that neutrophils of severely 
obese patients are less capable of activation and migration 
to target tissues rendering such patients more susceptible to 
inflammatory diseases.
In severely obese patients, enhanced numbers of macro-
phages have been reported in adipose tissue (6). In this context, 
the relation of activation of neutrophils with neutrophil infil-
tration of adipose and muscle tissue was investigated. Positive 
staining for MPO containing neutrophils in both adipose and 
skeletal muscle tissue was confined to blood vessels, which was 
similar in both tissues, indicating that the increased plasma 
MPO levels originate from other sources.
Interestingly, MPO is associated with cardiovascular dis-
eases, because elevated plasma MPO levels have been reported 
to predict the presence of coronary artery disease (9). In addi-
tion, it has been shown that low-density lipoprotein receptor 
knockout mice overexpressing MPO, given a high fat diet, 
had increased aortic lesions and were more obese than their 
low-density lipoprotein receptor knockout littermates (18). 
The latter was thought to result from effects of MPO on lipid 
metabolism.
Interestingly, both plasma MPO levels and obesity are 
 considered independent risk factors for cardiovascular disease. 
Increased plasma levels of MPO as observed in the present 
MPO
Preoperative 2 Years postoperative




























Figure 4 Effect of bariatric surgery on circulating plasma MPO and 
calprotectin levels. Preoperative and 2-year postoperative plasma levels 
of MPO and calprotectin were measured (study group 2). Two years 
after bariatric surgery, MPO levels remained unchanged after bariatric 
surgery (19.7 ± 4.1 ng/ml preoperative and 21.5 ± 6.8 ng/ml 2 years 
postoperative). Interestingly, calprotectin levels decreased (11 out of 
15 patients) significantly from a mean of 119.6 ± 31.5 to a mean of 
93.9 ± 42.7 ng/ml (P < 0.001). MPO, myeloperoxidase.
a
b
Figure 5 Immunohistochemical staining of (a) visceral adipose tissue 
and (b) muscle tissue of severely obese subjects showing that the 
MPO positive cells are restricted to the vasculature of these tissues 
(magnification ×200). MPO, myeloperoxidase.
2018 VOLUME 17 NUMBER 11 | NOVEMBER 2009 | www.obesityjournal.org
articles
intervention and Prevention
study could therefore imply an additional risk for obese indi-
viduals for cardiovascular diseases. In another perspective, the 
causative role of MPO in cardiovascular disease and obesity 
provides opportunities for treatment options aimed at decreas-
ing oxidative damage with antioxidants and related drugs (24), 
a topic that needs further study.
Bariatric surgery results in marked weight loss as well as 
decreased plasma levels of several inflammatory mediators 
(3,7). Therefore, we hypothesized that bariatric surgery would 
also result in decreased plasma levels of MPO and calprotec-
tin. The decreased plasma levels of calprotectin indeed indicate 
that neutrophils are less activated 2 years after bariatric surgery. 
However, similar to earlier observations that several parts of the 
inflammatory cascade do not decrease after substantial weight 
loss (3,7), MPO levels remained elevated 2 years after bariat-
ric surgery. This lack of effect of weight loss on plasma MPO 
 levels has also been described for obese subjects (BMI ~33) 
after both diet-induced as well as exercise-induced weight loss 
(25). On the other hand, Roberts et al. reported that weight 
loss of obese subjects (BMI ~35) through a combined diet and 
exercise intervention did result in decreased plasma MPO 
(26). Thus, weight loss induced by rigorous lifestyle interven-
tions may differentially modulate the inflammatory response 
as compared with weight loss through surgery. The contrasting 
effects of weight loss on plasma MPO vs.  calprotectin levels 
in our study may relate to the fact that MPO and calprotectin 
are subject to different release patterns, due to their different 
 location in the neutrophil.
In summary, we show that increased numbers of activated 
neutrophils are circulating in severely obese individuals. 
Bariatric surgery partly reduced neutrophil activation. These 
findings support the notion that morbid obesity is associated 
with activation of the innate immune response. Interestingly, 
the innate immune response is an acute inflammatory response, 
while obesity is considered a chronic inflammatory status. 
Therefore, obesity appears to be characterized by a chronic 
stimulation of the acute inflammatory response.
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